Research graph
References from Imaging xCT with Immuno-PET in Therapy-Resistant Non–Small Cell Lung Cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
10.1038/s41568-021-00435-0
10.1038/s41568-021-00435-0 · External reference
10.1016/j.ccell.2020.06.001
10.1016/j.ccell.2020.06.001 · External reference
10.1038/s41388-021-02055-2
10.1038/s41388-021-02055-2 · External reference
10.1158/0008-5472.can-10-0171
10.1158/0008-5472.can-10-0171 · External reference
10.1002/cbf.1149
10.1002/cbf.1149 · External reference
Emerging roles of NRF2 signal in non-small cell lung cancer
10.1186/s13045-016-0246-5 · 2016 · External reference
NRF2, the master regulator of anti-oxidative responses
10.3390/ijms18122772 · 2017 · External reference
10.1007/s00424-003-1086-z
10.1007/s00424-003-1086-z · External reference
Combination therapy with sulfasalazine and valproic acid promotes human glioblastoma cell death through imbalance of the intracellular oxidative response
10.1007/s12035-018-0895-1 · 2018 · External reference
10.1016/j.canlet.2015.07.031
10.1016/j.canlet.2015.07.031 · External reference
10.1111/cas.13728
10.1111/cas.13728 · External reference
10.1007/s10120-017-0720-y
10.1007/s10120-017-0720-y · External reference
Sulfasalazine and temozolomide with radiation therapy for newly diagnosed glioblastoma
10.4103/0028-3886.128280 · 2014 · External reference
Imaging NRF2 activation in non-small cell lung cancer with positron emission tomography
10.1038/s41467-024-54852-4 · 2024 · External reference
10.7150/thno.63237
10.7150/thno.63237 · External reference
10.1158/1078-0432.ccr-11-0687
10.1158/1078-0432.ccr-11-0687 · External reference
10.2967/jnumed.119.225870
10.2967/jnumed.119.225870 · External reference
10.2967/jnumed.122.265254
10.2967/jnumed.122.265254 · External reference
10.1158/0008-5472.can-18-2634
10.1158/0008-5472.can-18-2634 · External reference
[18F]FSPG-PET provides an early marker of radiotherapy response in head and neck squamous cell cancer
10.1038/s44303-024-00038-y · 2024 · External reference
Feasibility of [18F]FSPG PET for early response assessment to combined blockade of EGFR and glutamine metabolism in wild-type KRAS colorectal cancer
10.3390/tomography9020041 · 2023 · External reference
10.1038/nprot.2010.13
10.1038/nprot.2010.13 · External reference
10.1016/j.nucmedbio.2019.04.005
10.1016/j.nucmedbio.2019.04.005 · External reference
10.2967/jnumed.119.228692
10.2967/jnumed.119.228692 · External reference
10.1016/j.nucmedbio.2010.12.011
10.1016/j.nucmedbio.2010.12.011 · External reference
10.1158/0008-5472.can-17-1958
10.1158/0008-5472.can-17-1958 · External reference
10.1080/19420862.2017.1323159
10.1080/19420862.2017.1323159 · External reference
10.1371/journal.pone.0077476
10.1371/journal.pone.0077476 · External reference
10.1038/s41422-022-00642-w
10.1038/s41422-022-00642-w · External reference
10.1038/s41586-019-1011-z
10.1038/s41586-019-1011-z · External reference
10.1089/ars.2011.4391
10.1089/ars.2011.4391 · External reference
10.1182/blood-2005-02-0516
10.1182/blood-2005-02-0516 · External reference
10.2967/jnumed.118.223636
10.2967/jnumed.118.223636 · External reference
